ConductScience.org, home

Paper795537

Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity.

Weiss AJ and 5 others. Cancer Treat Rep, 1976. Cited by 164 papers, by iCite.

Cite this record

ConductScience Library. Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Papers, record 795537. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/795537

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity.
PubMed
Journal
Cancer Treat Rep
PubMed
Year
1976
PubMed
Publication types
Case Reports, Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
164
iCite
Relative citation ratio, by iCite
6.52
iCite
Revised in PubMed
2013-11-21
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Weiss AJA J
2Metter GEG E
3Fletcher WSW S
4Wilson WLW L
5Grage TBT B
6Ramirez GG

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
DoxorubicinMajor topic
Heart DiseasesMajor topic
Adult
Aged
Clinical Trials as Topic
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Leukopenia
Male
Middle Aged
Nausea
Neoplasms
Prognosis
Stomatitis
Thrombocytopenia

Source PubMed

Download CSV of topics

Cited by26

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 164 citations.

PMIDTitleJournalYearIn PapersSource
37383708Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review.Front Pharmacol2023https://conductscience.org/library/papers/37383708PubMed
33404976Multiscale and Translational Quantitative Systems Toxicology, Pharmacokinetic-Toxicodynamic Modeling Analysis for Assessment of Doxorubicin-Induced Cardiotoxicity.AAPS J2021https://conductscience.org/library/papers/33404976PubMed
23166343Continuous Versus Bolus Infusion of Doxorubicin in Children With ALL: Long-term Cardiac Outcomes.Pediatrics2012https://conductscience.org/library/papers/23166343PubMed
21737575Cardiovascular complications of breast cancer therapy in older adults.Oncologist2011https://conductscience.org/library/papers/21737575PubMed
16808550Heart failure induced by non-cardiac drugs.Drug Saf2006https://conductscience.org/library/papers/16808550PubMed
15977964Cardiotoxicity of cancer chemotherapy: implications for children.Paediatr Drugs2005https://conductscience.org/library/papers/15977964PubMed
10789823Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention.Drug Saf2000https://conductscience.org/library/papers/10789823PubMed
8968695A risk-benefit assessment of anthracycline antibiotics in antineoplastic therapy.Drug Saf1996https://conductscience.org/library/papers/8968695PubMed
8280512Anthracyclines and the heart.Br Heart J1993https://conductscience.org/library/papers/8280512PubMed
7340990Tissue distribution of doxorubicin and doxorubicinol in rats receiving multiple doses of doxorubicin.Cancer Chemother Pharmacol1981https://conductscience.org/library/papers/7340990PubMed
6961377Anthracycline cardiomyopathy.Pediatr Cardiol1982https://conductscience.org/library/papers/6961377PubMed
6590531Phase I trial of aclacinomycin-A. A clinical and pharmacokinetic study.Invest New Drugs1983https://conductscience.org/library/papers/6590531PubMed
6574828A simplified method for determination of daunorubicin, adriamycin, and their chief fluorescent metabolites in human plasma by high-pressure liquid chromatography.Cancer Chemother Pharmacol1983https://conductscience.org/library/papers/6574828PubMed
4058077Intrahepatic and intravenous administration of adriamycin--a comparative pharmacokinetic study in patients with malignant liver tumours.Med Oncol Tumor Pharmacother1985https://conductscience.org/library/papers/4058077PubMed
4052636Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment.Breast Cancer Res Treat1985https://conductscience.org/library/papers/4052636PubMed
3987800Pharmacokinetic study of i.v. infusions of adriamycin.Eur J Clin Pharmacol1985https://conductscience.org/library/papers/3987800PubMed
3888428Anticancer drug pharmacodynamics.Cancer Chemother Pharmacol1985https://conductscience.org/library/papers/3888428PubMed
3555940Pharmacokinetics of anticancer drugs in children.Clin Pharmacokinet1987https://conductscience.org/library/papers/3555940PubMed
3520474Anthracycline antitumour agents. A review of physicochemical, analytical and stability properties.Pharm Weekbl Sci1986https://conductscience.org/library/papers/3520474PubMed
3463436Cellular and plasma pharmacokinetics of weekly 20-mg 4'-epi-adriamycin bolus injection in patients with advanced breast carcinoma.Cancer Chemother Pharmacol1986https://conductscience.org/library/papers/3463436PubMed

See all 26 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/795537

GET https://conductscience.org/api/papers/v1/795537/cited_by?page=2